|

BL-B01D1 for Injection Clinical Trials

1 actively recruiting trial

Also known as: BMS-986507, iza-bren, izalontamab brengitecan

Pipeline

Phase 2: 1

Top Sponsors

  • Sichuan Baili Pharmaceutical Co., Ltd.1

Indications

  • Recurrent Glioblastoma1
  • Cancer1

Other1 trial

A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.